Research programme: RNA interference-based therapeutics - Antigen Express

Drug Profile

Research programme: RNA interference-based therapeutics - Antigen Express

Alternative Names: Ii suppression - Antigen Express

Latest Information Update: 23 Jan 2013

Price : $50

At a glance

  • Originator Antigen Express
  • Class DNA vaccines; Small interfering RNA
  • Mechanism of Action Helper-inducer T-lymphocyte stimulants; Invariant chain inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; HIV infections

Most Recent Events

  • 01 Jan 2011 Preclinical trials in HIV infections in USA (Parenteral)
  • 29 Aug 2008 Preclinical development in Acute myeloid leukaemia is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top